Investors sue Solid Biosciences, say they were duped about Duchenne drug’s safety
March 28, 2018 at 16:19 PM EDT
The Cambridge biotech raised $125 million in an IPO in January, but saw its stock price plummet earlier this month after disclosing that the FDA had halted a trial of the drug.
